GSK Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of 21.61% compared to GSK PLC's net margin of -227.46%. GSK PLC's return on equity of 23.08% beat BioNTech SE's return on equity of -3.91%.

GSK PLC has a consensus price target of $41.72, signalling upside risk potential of 8.98%. On the other hand BioNTech SE has an analysts' consensus of $136.00 which suggests that it could grow by 20.9%. Given that BioNTech SE has higher upside potential than GSK PLC, analysts believe BioNTech SE is more attractive than GSK PLC.

GSK PLC has a beta of 0.514, which suggesting that the stock is 48.644% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.283, suggesting its more volatile than the S&P 500 by 28.318%.

GSK PLC has a quarterly dividend of $0.43 per share corresponding to a yield of 4.18%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $9.5B, which are larger than BioNTech SE quarterly revenues of $192.3M. GSK PLC's net income of $2B is higher than BioNTech SE's net income of -$437.5M. Notably, GSK PLC's price-to-earnings ratio is 19.85x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.97x versus 9.12x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 21.61% compared to GSK PLC's net margin of -907.48%. GSK PLC's return on equity of 23.08% beat Moderna's return on equity of -29.23%.

GSK PLC has a consensus price target of $41.72, signalling upside risk potential of 8.98%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 48.44%. Given that Moderna has higher upside potential than GSK PLC, analysts believe Moderna is more attractive than GSK PLC.

GSK PLC has a beta of 0.514, which suggesting that the stock is 48.644% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

GSK PLC has a quarterly dividend of $0.43 per share corresponding to a yield of 4.18%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $9.5B, which are larger than Moderna quarterly revenues of $107M. GSK PLC's net income of $2B is higher than Moderna's net income of -$971M. Notably, GSK PLC's price-to-earnings ratio is 19.85x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.97x versus 3.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

NuCana PLC has a net margin of 21.61% compared to GSK PLC's net margin of --. GSK PLC's return on equity of 23.08% beat NuCana PLC's return on equity of --.

GSK PLC has a consensus price target of $41.72, signalling upside risk potential of 8.98%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 207071.32%. Given that NuCana PLC has higher upside potential than GSK PLC, analysts believe NuCana PLC is more attractive than GSK PLC.

GSK PLC has a beta of 0.514, which suggesting that the stock is 48.644% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.561%.

GSK PLC has a quarterly dividend of $0.43 per share corresponding to a yield of 4.18%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $9.5B, which are larger than NuCana PLC quarterly revenues of --. GSK PLC's net income of $2B is higher than NuCana PLC's net income of -$3.1M. Notably, GSK PLC's price-to-earnings ratio is 19.85x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.97x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of 21.61% compared to GSK PLC's net margin of 82.81%. GSK PLC's return on equity of 23.08% beat Novavax's return on equity of --.

GSK PLC has a consensus price target of $41.72, signalling upside risk potential of 8.98%. On the other hand Novavax has an analysts' consensus of $13.43 which suggests that it could grow by 92.94%. Given that Novavax has higher upside potential than GSK PLC, analysts believe Novavax is more attractive than GSK PLC.

GSK PLC has a beta of 0.514, which suggesting that the stock is 48.644% less volatile than S&P 500. In comparison Novavax has a beta of 2.691, suggesting its more volatile than the S&P 500 by 169.079%.

GSK PLC has a quarterly dividend of $0.43 per share corresponding to a yield of 4.18%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $9.5B, which are larger than Novavax quarterly revenues of $626.3M. GSK PLC's net income of $2B is higher than Novavax's net income of $518.6M. Notably, GSK PLC's price-to-earnings ratio is 19.85x while Novavax's PE ratio is 2.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.97x versus 0.95x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.